Vascepa is a prescription drug that contains the active ingredient icosapent ethyl, which is used to treat high levels of triglycerides in the blood. There are some restrictions on the use of Vascepa, as well as limitations on coverage by Medicare.

According to the drug patent watch website [1], Vascepa is currently protected by a patent that is set to expire in 2030. This means that other companies are not allowed to produce and sell generic versions of the drug until the patent expires.

The Vascepa website [2] states that the drug is indicated as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia (triglyceride levels greater than or equal to 500 mg/dL). It is also indicated as an adjunct to maximally tolerated statin therapy to reduce the risk of cardiovascular events in adult patients with elevated triglyceride levels (150-499 mg/dL) and other risk factors for cardiovascular disease.

However, there are some restrictions on the use of Vascepa. For example, the drug should not be used in patients with a known hypersensitivity to icosapent ethyl or any of its components. It should also be used with caution in patients with hepatic impairment or a history of pancreatitis.

In terms of coverage by Medicare, the GoodRx website [3] states that Vascepa is covered by Medicare Part D plans, but there may be restrictions on coverage depending on the specific plan. Patients may need to meet certain criteria or try other medications before Vascepa is covered by their plan.

In summary, Vascepa is a prescription drug used to treat high levels of triglycerides in the blood. While there are some restrictions on its use, it is generally well-tolerated and effective. Medicare coverage for Vascepa may vary depending on the specific plan.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/VASCEPA
[2] https://www.vascepa.com/
[3] https://www.goodrx.com/vascepa/medicare-coverage